Loss of MSH3 function is an acquired somatic defect seen in 50% of colorectal cancers and triggered by proinflammatory interleukin-6 signaling, causing a reversible nuclear-to-cytoplasmic shift of the protein. Here, MSH3 is linked to colorectal cancer.